Submitted to :
Submitted by :
Submitted to :
Submitted by :
Traded as| BSE : 524715 NSE: sunpharma|
Founder| Dilip Shanghvi|
Headquarters| Mumbai, India.|
Key people| Chairman : Israel Makov , MD : Dilip Shanghvi| Products| Pharmaceuticals, Generic drugs|
Revenue| INR 8500 crore|
Net income| INR 2972 crore|
Fundamental analysis involves analyzing the underlying forces that affect the well-being of the economy, industry groups, and companies. Most often, the aim of company analysis is to derive a stock's current fair value and forecast future value. If fair value is not equal to the current stock price, fundamental analysts believe that the stock is either over or under valued and the market price will ultimately gravitate towards fair value. By believing that prices do not accurately reflect all available information, fundamental analysts look to capitalize on perceived price discrepancies. In this project an attempt has been made to analyzed financial performance of Sun Pharmaceuticals Industries limited. Earlier part of the report gives information about Indian economy and industry scenario. The later part of the project gives information about company financial performance and ratios analysis. This study will help us to determine the financial health of a company.
Indian Pharmaceutical Industry Overview:
The Indian Pharmaceutical Industry today is in the front rank of India’s science-based industries with wide ranging capabilities in the complex field of drug manufacture and technology. A highly organized sector, the Indian Pharma Industry is estimated to be worth $ 4.5 billion, growing at about 8 to 9 percent annually. It ranks very high in the third world, in terms of technology, quality and range of medicines manufactured. From simple headache pills to sophisticated antibiotics and complex cardiac compounds, almost every type of medicine is now made indigenously.Playing a key role in promoting and sustaining development in the vital field of medicines, Indian Pharma Industry boasts of quality producers and many units approved by regulatory authorities in USA and UK.
International companies associated with this sector have stimulated, assisted and spear headed this dynamic development in the past 53 years and helped to put India on the pharmaceutical map of the world. The Indian Pharmaceutical sector is highly fragmented with more than20,000 registered units. It has expanded drastically in the last two decades. The leading 250 pharmaceutical companies control 70% of the market with market leader holding nearly 7% of the market share. It is an extremely fragmented market with severe price competition and government price control. The pharmaceutical industry in India meets around 70% of the country's demand for bulk drugs, drug intermediates, pharmaceutical formulations, chemicals, tablets, capsules, orals and injectibles. There are about 250 large units and about 8000 Small Scale Units, which form the core of the pharmaceutical industry in India (including 5 Central Public Sector Units). These units produce the complete range of pharmaceutical formulations, i.e., medicines ready for consumption by patients and about 350 bulk drugs, i.e., chemicals having therapeutic value and used for production of pharmaceutical formulations.
Environmental Analysis (PEST):